United States Patent 5,658,590: Scope, Claims, Expiration, Litigation, and Atomoxetine Patent Landscape

United States Patent No. 5,658,590 covered the use of tomoxetine, now known as atomoxetine, to treat attention-deficit/hyperactivity disorder. Its 16 claims were method-of-treatment claims directed to ADHD generally and to three diagnostic subtypes across children, adolescents, and adults. The patent did not claim a new chemical entity, dosage form, dose, formulation, manufacturing process, or specific administration schedule.

The patent has expired. Its historical Orange Book-listed expiration date was May 27, 2017, with pediatric exclusivity extending the associated regulatory protection through November 27, 2017. Generic atomoxetine products entered the U.S. market after that protection ended. The patent therefore has no current blocking effect on U.S. atomoxetine development or commercialization. [1][2]

What drug and therapeutic use did U.S. Patent 5,658,590 protect?

U.S. Patent 5,658,590 protected the use of tomoxetine for treating ADHD. Tomoxetine is the former development name for atomoxetine, a selective norepinephrine reuptake inhibitor marketed by Eli Lilly and Company as Strattera.

The patent’s central claim was:

A method of treating attention-deficit/hyperactivity disorder comprising administering to a patient in need of such treatment an effective amount of tomoxetine.

The patent was a second-generation use patent. Earlier atomoxetine-related patent rights covered the compound or chemical class. Patent 5,658,590 instead focused on the previously unclaimed therapeutic use of the compound in ADHD.

Item	Details
U.S. patent	5,658,590
Title	Treatment of attention deficit hyperactivity disorder with tomoxetine
Patent holder	Eli Lilly and Company
Active ingredient	Tomoxetine, now called atomoxetine
Therapeutic area	Attention-deficit/hyperactivity disorder
Claim type	Method of treatment
Issue date	August 19, 1997
Historical Orange Book expiration	May 27, 2017
Pediatric exclusivity	Through November 27, 2017
Current status	Expired
FDA product associated with patent	Strattera capsules and related atomoxetine products

What do the 16 claims of Patent 5,658,590 cover?

The claims divide into one broad independent claim and 15 dependent claims.

Claim 1: broad ADHD treatment method

Claim 1 covers administering an effective amount of tomoxetine to a patient who requires treatment for ADHD.

The claim does not specify:

A particular dose
A dosing frequency
Oral or nonoral administration
A specific formulation
Atomoxetine hydrochloride versus another pharmaceutically acceptable form
Monotherapy or combination therapy
A required treatment duration
A particular disease-severity threshold
A biomarker or diagnostic test
A specific clinical endpoint

The principal limitations are therefore the drug, the disease, the patient population, and the therapeutic purpose.

Claims 2 through 4: ADHD diagnostic subtypes

Claims 2, 3, and 4 narrow claim 1 to the three ADHD categories identified in the patent:

Claim	Covered subtype
2	Predominantly inattentive type
3	Predominantly hyperactive-impulsive type
4	Combined type

These claims do not create separate composition rights. They are narrower method claims that require the treated patient to fall within the specified ADHD subtype.

Claims 5 through 8: adults

Claim 5 limits claim 1 to adult patients. Claims 6 through 8 combine adult patients with the three ADHD subtypes:

Claim 6: adults with predominantly inattentive ADHD
Claim 7: adults with predominantly hyperactive-impulsive ADHD
Claim 8: adults with combined-type ADHD

Claims 9 through 12: adolescents

Claim 9 limits the treatment method to adolescents. Claims 10 through 12 add the same three subtype limitations:

Claim 10: adolescents with predominantly inattentive ADHD
Claim 11: adolescents with predominantly hyperactive-impulsive ADHD
Claim 12: adolescents with combined-type ADHD

Claims 13 through 16: children

Claim 13 limits the treatment method to children. Claims 14 through 16 cover the three corresponding subtypes:

Claim 14: children with predominantly inattentive ADHD
Claim 15: children with predominantly hyperactive-impulsive ADHD
Claim 16: children with combined-type ADHD

How broad is the scope of Patent 5,658,590?

The patent had broad therapeutic-use scope but limited claim-category scope.

Broad elements

Claim 1 was broad because it did not impose a narrow treatment protocol. A potentially infringing use could have involved:

Any effective amount of tomoxetine
Any clinically appropriate dosing schedule
Any route permitted by the claim construction
Any formulation containing tomoxetine
Adult, adolescent, or child patients
Any of the three identified ADHD subtypes or ADHD generally

The claim also did not require a particular response rate, symptom score, or treatment duration.

Limiting elements

The patent did not cover every use of atomoxetine. It required:

A patient in need of ADHD treatment.
Administration of tomoxetine.
An effective amount.
A therapeutic purpose directed to ADHD.

Uses for depression, anxiety, urinary incontinence, narcolepsy, or other conditions were outside the express scope of these claims unless the factual use also constituted treatment of ADHD.

The patent also did not independently protect:

The atomoxetine molecule as a chemical entity
Atomoxetine hydrochloride as a composition
A capsule or tablet formulation
A manufacturing process
A method of reducing adverse events
A dose titration schedule
A specific pharmacokinetic profile

Did the claims cover atomoxetine hydrochloride?

Commercial atomoxetine products are generally administered as atomoxetine hydrochloride. The patent claims use the term tomoxetine, the former generic designation for atomoxetine.

In practical patent analysis, the relevant question was whether administration of the marketed salt constituted administration of the claimed active ingredient. For a method claim directed to treatment with the active pharmaceutical ingredient, use of the hydrochloride salt would ordinarily be the commercial embodiment evaluated against the claim.

The patent’s lack of a salt-specific limitation made the claims materially broader than a claim limited to one crystalline form, salt, particle size, or formulation. A generic manufacturer would therefore have faced an infringement issue based on the labeled ADHD use, not merely on the composition of its capsule.

What was the Orange Book status of U.S. Patent 5,658,590?

Patent 5,658,590 was listed in the FDA Orange Book for Strattera as a use patent. The listing supported regulatory patent certifications by ANDA applicants seeking approval for generic atomoxetine.

Regulatory issue	Historical position
FDA product	Strattera
Patent listing type	Method-of-use patent
ANDA relevance	Paragraph IV or other applicable certification
Patent expiration	May 27, 2017
Pediatric exclusivity end	November 27, 2017
Current blocking status	None; expired

The listing did not mean that Eli Lilly owned a perpetual right to prevent all atomoxetine products. It concerned the approved ADHD use associated with Strattera.

The Drug Price Competition and Patent Term Restoration Act requires an ANDA applicant to address listed patents through certifications under 21 U.S.C. § 355(j)(2)(A)(vii). A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A section viii statement can sometimes carve out a patented method of use, but that strategy is difficult where ADHD is the central and labeled use of atomoxetine. [3]

When did Patent 5,658,590 lose exclusivity?

The patent’s historical expiration date was May 27, 2017. Six months of pediatric exclusivity followed, extending the associated exclusivity period to November 27, 2017.

The commercial exclusivity sequence was therefore:

Date	Event
August 19, 1997	Patent issued
November 26, 2002	FDA approved Strattera for ADHD
May 27, 2017	Patent term ended
November 27, 2017	Six-month pediatric exclusivity ended
Late 2017 onward	Generic atomoxetine competition expanded

The patent did not remain enforceable after expiration. Any later commercial risk would have depended on other unexpired patents, regulatory exclusivity, trade secrets, or non-patent restrictions rather than Patent 5,658,590.

Which companies challenged the Strattera patent?

Multiple generic-drug companies pursued atomoxetine ANDA strategies before or around patent expiry. Public generic competition included products from manufacturers such as Teva, Apotex, Aurobindo, Sandoz, Wockhardt, Zydus, and other ANDA sponsors.

Paragraph IV activity in this area was commercially important because the patent was a use patent attached to the principal approved indication. The commercial value of a challenge depended on whether the applicant could:

Invalidate the patent
Establish noninfringement
Obtain approval after expiration
Use a permissible label carveout
Resolve the matter through a settlement or litigation outcome

The historical record includes ANDA-related disputes involving Eli Lilly and generic applicants. The patent’s expiration ultimately removed the central obstacle to broad-label atomoxetine competition. Because the patent is expired, prior Paragraph IV disputes no longer create present launch risk under this patent.

What litigation and settlement issues affected atomoxetine?

The principal litigation theory would have involved alleged infringement of the method claims by an ANDA applicant whose proposed labeling instructed use of atomoxetine for ADHD.

The relevant litigation questions included:

Whether the generic label induced use covered by claim 1
Whether the label covered one or more of the dependent age or subtype claims
Whether the patent was valid in view of prior art
Whether the claimed ADHD use was adequately supported by the patent disclosure
Whether the patent was enforceable
Whether a generic applicant could use a narrower indication or label carveout

Settlement agreements in pharmaceutical patent disputes can delay generic launch, permit an agreed entry date, or establish commercial terms. Public patent records and FDA approval data should be reviewed together when reconstructing a specific settlement. Patent 5,658,590 itself no longer supports a current injunction or launch delay because its term has ended.

What other patents protected atomoxetine and Strattera?

Patent 5,658,590 was one part of the atomoxetine estate. The broader landscape historically included several categories.

Compound and chemical-class patents

Earlier Lilly patents covered substituted phenyl compounds, including atomoxetine or related chemical classes. Those rights were materially earlier than the ADHD use patent and had expired before or around the initial commercial life of Strattera.

Use patents

Patent 5,658,590 was the principal ADHD method patent identified in the supplied claim set. Other use claims may have addressed different therapeutic applications or patient populations, depending on the relevant filing and prosecution history.

Formulation patents

Formulation protection can cover:

Atomoxetine hydrochloride compositions
Capsule dosage forms
Excipients
Release characteristics
Stability improvements
Manufacturing processes

A formulation patent requires separate claim-by-claim analysis. Patent 5,658,590 does not itself require any particular formulation and should not be treated as a formulation patent.

Regulatory exclusivity

Strattera also benefited from FDA regulatory exclusivity associated with approval and pediatric studies. Regulatory exclusivity is distinct from patent protection. It can delay approval or marketing even when a patent does not block the product.

How does atomoxetine patent protection compare with stimulant ADHD drugs?

Atomoxetine differs from methylphenidate and amphetamine products in both pharmacology and patent risk.

Issue	Atomoxetine	Methylphenidate and amphetamine products
Primary class	Selective norepinephrine reuptake inhibitor	Stimulants
U.S. product	Strattera	Multiple branded and generic products
Key patent type	ADHD method-of-use patent	Compound, formulation, release-profile, and method patents
Controlled substance	No	Generally controlled substances
Generic pathway	ANDA	ANDA, often with formulation-specific disputes
Biosimilar pathway	Not applicable	Not applicable
Current Patent 5,658,590 risk	None; expired	Depends on product-specific patents

Atomoxetine is a small molecule. A biosimilar pathway does not apply. Generic competition proceeds through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not through the biologics license application and biosimilar framework.

How strong was the patent estate for Patent 5,658,590?

The patent was commercially strong while in force because claim 1 covered the core approved use without requiring a narrow dose or formulation. Its weaknesses were structural:

It was limited to a method of treating ADHD.
It did not cover the molecule itself.
It did not cover non-ADHD uses.
Its validity depended on the patentability and disclosure of the ADHD indication.
Its term was finite and could not permanently prevent generic atomoxetine.

The dependent claims added coverage for age groups and ADHD subtypes but did not materially expand the claim category. Their value was defensive: they provided narrower fallback positions if claim 1 faced validity or construction problems.

What generic launch risks remain today?

Patent 5,658,590 creates no current generic launch risk. A company launching atomoxetine in the United States must instead evaluate:

Current Orange Book listings for the relevant product
Any later-issued formulation or manufacturing patents
FDA labeling requirements
Bioequivalence
Capsule strength and dosage-form requirements
REMS or postmarketing obligations, if applicable
State substitution and controlled-substance rules, although atomoxetine is not federally controlled
Product-liability and pharmacovigilance exposure

For a conventional atomoxetine capsule, the principal patent obstacle historically associated with the ADHD indication was removed when the patent and pediatric exclusivity expired.

Key Takeaways

U.S. Patent 5,658,590 claimed treatment of ADHD with tomoxetine, now called atomoxetine.
Claim 1 was a broad method-of-treatment claim covering administration of an effective amount to a patient requiring ADHD treatment.
Claims 2 through 16 narrowed the method by ADHD subtype and patient age.
The patent did not claim atomoxetine as a molecule, a specific salt, a formulation, a dose, or a manufacturing process.
The historical Orange Book expiration date was May 27, 2017.
Pediatric exclusivity extended the associated protection through November 27, 2017.
The patent is expired and does not create a current U.S. launch barrier.
Atomoxetine is a small molecule and is subject to the ANDA pathway, not biosimilar regulation.
Historical Paragraph IV and ANDA disputes focused on whether generic labeling would induce infringement of the ADHD method claims.
Current diligence should focus on later Orange Book listings, formulation patents, regulatory requirements, and commercial execution rather than Patent 5,658,590.

FAQs About U.S. Patent 5,658,590 and Atomoxetine

Did Patent 5,658,590 cover Strattera itself?

No. It covered a method of using tomoxetine to treat ADHD. It did not claim the atomoxetine molecule as a composition of matter.

Did the patent cover adult ADHD treatment?

Yes. Claim 5 covered treatment of adult patients, and claims 6 through 8 addressed the three specified ADHD subtypes in adults.

Did the patent cover pediatric ADHD treatment?

Yes. Claims 9 through 16 covered adolescents and children, including the inattentive, hyperactive-impulsive, and combined types.

Could a generic company avoid the patent by using a different capsule formulation?

Not necessarily. The claims did not require a particular formulation. A different capsule formulation could still have implicated the method claims if the product was labeled and used to treat ADHD during the patent term.

Is a biosimilar application required for atomoxetine?

No. Atomoxetine is a chemically synthesized small molecule. A generic applicant uses the FDA ANDA pathway rather than the biosimilar pathway.

References

U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,658,590: Treatment of attention deficit hyperactivity disorder with tomoxetine. U.S. Department of Commerce.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j) (2024).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0721777	⤷ Start Trial	SPC/GB04/033	United Kingdom	⤷ Start Trial
European Patent Office	0721777	⤷ Start Trial	300180	Netherlands	⤷ Start Trial
European Patent Office	0721777	⤷ Start Trial	91238	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,658,590

Summary for Patent: 5,658,590